26 Aug 2021 Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
26 Aug 2021 Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
26 Aug 2021 Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
24 Aug 2021 BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine
24 Aug 2021 Nouscom announces first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer
23 Aug 2021 Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine
23 Aug 2021 Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adjuvant
23 Aug 2021 Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
23 Aug 2021 Valneva Commences Rolling Submission to MHRA for its Inactivated, Adjuvanted COVID-19 Vaccine
21 Aug 2021 Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world
20 Aug 2021 Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern
19 Aug 2021 Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates
17 Aug 2021 Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
17 Aug 2021 Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
14 Aug 2021 U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine
13 Aug 2021 Moderna Announces New Study Showing Its COVID-19 Vaccine Maintains Antibodies Against Variants of Concern and Interest to 6 Months
12 Aug 2021 Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
10 Aug 2021 YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from New Zealand
10 Aug 2021 SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations
06 Aug 2021 Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine
06 Aug 2021 Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination
05 Aug 2021 INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease
05 Aug 2021 Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
02 Aug 2021 FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate
02 Aug 2021 Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up